Auranofin: 1 mg or 9 mg? The search for the appropriate dose

A. Calin, D. Saunders, R. Bennett

    Research output: Contribution to journalArticle

    16 Scopus citations

    Abstract

    Auranofin (AF) was given to 2 groups of patients, one receiving 1 mg daily (56 patients), the other 9 mg (60 patients) in a double-blind manner. Significantly fewer patients on 1 mg (7%) reduced dosage or dropped out because of side effects than did those on high dose (27%; p < 0.05). Dropouts related to skin rash while dose reduction was necessitated by self-limiting diarrhea. Significantly more patients on low dose dropped out because of lack of efficacy than did those on high dose.

    Original languageEnglish (US)
    Pages (from-to)146-148
    Number of pages3
    JournalJournal of Rheumatology
    Volume9
    Issue numberSuppl. 8
    StatePublished - Jan 1 1982

    ASJC Scopus subject areas

    • Rheumatology
    • Immunology and Allergy
    • Immunology

    Fingerprint Dive into the research topics of 'Auranofin: 1 mg or 9 mg? The search for the appropriate dose'. Together they form a unique fingerprint.

  • Cite this

    Calin, A., Saunders, D., & Bennett, R. (1982). Auranofin: 1 mg or 9 mg? The search for the appropriate dose. Journal of Rheumatology, 9(Suppl. 8), 146-148.